Canadian Respiratory Journal / 2018 / Article / Tab 1

Research Article

The Serum Level of IL-1B Correlates with the Activity of Chronic Pulmonary Aspergillosis

Table 1

Clinical characteristics of subjects with CPA in the whole and subgroup analysis.

Whole group ()Total ()Subgroup value
Serum IL-1B ≥ 20.3 ng/L ()Serum IL-1B < 20.3 ng/L ()

Age, years57 (48.0, 66.0)55 (42.0, 62.0)56.5 (46.0, 62.0)50.5 (40.3, 63.0)0.356
Gender, male279 (59.5)52 (59.1)24 (54.5)28 (63.6)0.386
BMI, kg/m221.1 ± 3.621.4 ± 3.921.6 ± 4.121.3 ± 3.80.729
Smoking history, yes, pulmonary underlying diseases144 (30.7)26 (29.5)11 (25.0)15 (34.1)0.350
TBTreated180 (38.4)40 (45.5)22 (50.0)18 (40.9)0.392
Active87 (18.6)
 NTM infection30 (6.4)
 Other acute  respiratory  infections59 (12.6)
 Lung abscess12 (2.6)
 Cancers60 (12.8)
 COPDStable212 (45.2)47 (53.4)24 (54.5)23 (52.3)0.831
Acute53 (11.3)
 Sarcoidosis34 (7.3)5 (5.7)2 (4.5)3 (6.8)1.000
 AIP12 (2.6)
Other ILD53 (11.3)4 (4.8)3 (6.8)1 (2.3)0.616
Systemic comorbidities
DM53 (11.3)7 (8.0)3 (6.8)4 (9.1)1.000
Hypertension60 (12.8)14 (15.9)6 (13.6)8 (18.2)0.560
Cardiac diseases60 (12.8)9 (10.2)3 (6.8)6 (13.6)0.484
 Cerebrovascular  diseases14 (2.98)2 (2.3)0 (0)2 (4.5)0.494
Systemic CS therapy36 (7.7)
Systemic IS therapy32 (6.8)
Pulmonary surgery history38 (8.1)9 (10.2)2 (4.5)7 (15.9)0.157
Symptoms
Cough460 (98.1)85 (96.6)44 (100)41 (93.2)0.241
Sputum production455 (97.0)82 (93.2)42 (95.5)40 (90.9)0.676
Hemosputum272 (58.0)45 (51.1)26 (59.1)19 (43.2)0.135
Fever158 (33.7)19 (21.6)8 (18.2)11 (25.0)0.437
Chest pain58 (12.36)5 (5.68)2 (4.5)3 (6.8)1.000
Fatigue79 (16.8)4 (4.5)3 (6.8)1 (2.3)0.616
Radiological features
Cavity235 (50.1)40 (45.5)27 (61.4)13 (29.5)0.003
Aspergilloma212 (45.2)36 (40.9)25 (56.8)11 (25.0)0.002
Bronchiectasis408 (87.0)83 (94.3)23 (52.3)23 (52.3)1.000
Patch451 (96.2)82 (93.2)43 (97.7)39 (88.6)0.091
Consolidation363 (77.4)60 (68.2)27 (61.4)33 (75.0)0.170
Nodules332 (70.8)58 (65.9)31 (70.5)27 (61.4)0.368
Tree-in-bud pattern85 (18.1)8 (9.1)3 (6.8)5 (11.4)0.713
Atelectasis28 (6.0)3 (3.40)0 (0)3 (6.8)0.241
Pleural effusion79 (16.8)8 (9.1)5 (11.4)3 (6.8)0.713
Pleural thickening192 (40.9)39 (44.3)22 (50)17 (38.6)0.283
Interstitial fibrosis53 (11.3)4 (4.8)2 (4.5)2 (4.5)1.000
Lung volume reduction47 (10.0)6 (6.8)2 (4.5)4 (9.1)0.676
GGO53 (11.3)8 (9.1)2 (4.5)6 (13.6)0.266
Cavity diameter (cm)3.6 (2.6, 4.8)3.4 (2.1, 4.8)4.6 (2.8, 5.0)2.0 (1.6, 2.7)0.000
Aspergilloma size (cm)2.4 (1.7, 3.3)1.8 (1.5, 3.5)2.5 (1.6, 3.8)1.5 (0.9, 1.9)0.006
Cavity wall thickness (cm)0.7 (0.5, 1.0)0.7 (0.3, 1.1)0.9 (0.4, 1.2)0.4 (0.2, 0.7)0.023
G test, positive95 (20.3)16 (18.2)9 (20.5)7 (15.9)0.580
GM test, positive
Blood211 (45.0)43 (48.9)25 (56.8)18 (40.9)0.135
BWF338 (72.1)60 (68.2)32 (72.7)28 (63.6)0.360
Aspergillus antibody, positive276 (58.8)55 (62.5)25 (56.8)30 (68.2)0.271
Culture proof
Sputum177 (37.7)32 (36.4)17 (38.6)15 (34.1)0.658
BWF165 (35.2)32 (36.4)19 (43.2)13 (29.5)0.184
Laboratory test result
ALB39.1 ± 5.738.9 ± 5.638.6 ± 4.939.1 ± 6.20.699
WBC7.2 (5.4, 9.3)7.5 (5.3, 9.0)7.1 (5.1, 9.6)8.0 (5.4, 8.8)0.867
CRP6.9 (2.7, 20.4)5.9 (2.1, 18.8)5.8 (2.0, 26.2)6.0 (2.4, 8.3)0.987
ESR33.3 (16.4, 51.3)26.9 (11.8, 51.6)26.3 (11.5, 50.0)30.7 (12.2, 52.7)0.739
Inflammatory cytokines (ng/l)
IL-1B26.1 (15.2, 50.6)20.3 (15.2, 42.3)42.2 (25.2, 57.6)15.2 (11.7, 17.3)0.000
IL-2144.9 (102.2, 193.1)110.9 (75.1, 159.8)112.5 (76.3, 161.1)101.0 (69.9, 147.3)0.413
IL-539.2 (26.8, 62.3)37.7 (26.4, 61.5)46.8 (27.0, 62.4)32.8 (25.1, 50.1)0.090
IL-645.6 (23.0, 94.8)39.8 (26.7, 73.9)56.0 (27.6, 77.2)33.9 (24.6, 66.6)0.123
TNF-α52.3 (30.3, 96.1)53.6 (33.7, 90.0)65.4 (33.5, 96.0)46.5 (33.9, 79.4)0.174
γ-IFN16.6 (11.6, 27.5)17.8 (11.8, 27.0)20.0 (11.9, 31.4)16.8 (11.7, 22.3)0.129

Data are presented as mean ± standard deviation or median (interquartile range) or number (percentage). AIP: acute interstitial pneumonia; ALB: albumin; BMI: body mass index; BWF: bronchial washing fluid; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; CS: corticosteroid; DM: diabetes mellitus; ESR: erythrocyte sedimentation rate; GGO: ground glass opacity; IFN: interferon; IL: interleukin; ILD: interstitial lung disease; IS: immunosuppressive; NTM: nontuberculous mycobacterium; TB: tuberculosis; TNF: tumor necrosis factor; WBC: white blood cell.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.